| |
Financial Year 2009 - 2010
Quarter I
(June 2009)
Financial Year 2008 - 2009
Quarter IV
(March 2009)
Quarter III
(December 2008)
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
31st DECEMBER 2005
| Sl.No |
Particulars |
Quarter ended
31st December 05
(Un audited) |
Nine months ended
31st December 05
(Un audited) |
| 1 |
Sales (net) |
3405.66 |
7999.45 |
| 2 |
Other Income |
1091.03 |
1309.78 |
| 3 |
Total Expenditure |
2968.74 |
6661.24 |
| |
a) (Increase) / Decrease in Stock |
(81.24) |
(281.98) |
| |
b) Consumption of Raw materials |
2165.19 |
4893.96 |
| |
c) Staff Cost |
290.13 |
667.20 |
| |
d) Other Expenditure |
594.66 |
1382.06 |
| 4 |
Profit before R&D, Interest & Depreciation (1+2-3) |
1527.95 |
2647.99 |
| 5 |
Research and Development Expenditure |
104.54 |
246.26 |
| 6 |
Interest |
99.98 |
138.47 |
| 7 |
Depreciation & Amortisation |
94.26 |
232.62 |
| 8 |
Profit before Tax (4-5-6-7) |
1229.17 |
2030.64 |
| 9 |
Provision for Tax |
221.06 |
325.75 |
| 10 |
Profit after Tax before share in Associates (8-9) |
1008.11 |
1704.89 |
| 11 |
Less : Share of loss in Associate |
3.28 |
3.72 |
| 12 |
Net Profit (10-11) |
1004.83 |
1701.17 |
| 13 |
Equity Capital |
306.47 |
306.47 |
| 14 |
E.P.S (Face value - Rs.2/-) |
|
|
| |
- Basic - Not annualised |
6.71 |
11.36 |
| |
Annualised |
14.14 |
13.76 |
| |
- Diluted - Not annualised |
6.53 |
11.09 |
| |
Annualised |
13.74 |
13.41 |
| 15 |
Aggregate of Non promoters Shareholding |
|
|
| |
Number of shares |
55404520 |
55404520 |
| |
Face Value - Rs. |
2/- |
2/- |
| |
Percentage of Shareholding |
36.16% |
36.16% |
|
Notes :
| 1 |
The above unaudited consolidated results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 30th January 2006. |
| 2 |
The Consolidated accounts include the financial results of Docpharma N.V, (100% subsidiary) and Explora Laboratories SA, (43% stake - an Associate) for the entire quarter and Astrix Laboratories Ltd., (50% JV) from 30th Dec 2005. |
| 3 |
The above results are after accounting for certain exceptional and earlier period items crystallised during the quarter, the aggregate of which impact the Profit after tax (favourably) by Rs.633.70 millions. These include sale of knowhow, intangibles, investments, customer rate differences, claims etc. The favorable impact on EPS on account of these items amounts to Rs.4.23 (Basic) and Rs. 4.12 (Diluted), which is included in the quarter/ annualised EPS. |
| 4 |
Annualised EPS for the quarter and nine months ended December 2005 is arrived at without annualising the EPS in respect of exceptional items mentioned in note 3 above. |
| |
